Acura Pharmaceuticals, Inc. (Nasdaq:ACUR)
September 10th, 2018
Acura Pharmaceuticals, Inc. fell $0.03 Tuesday, down 22.23%, closing at $0.10. Acura Pharmaceuticals, Inc. swung 50.00% between low and high. Sadly, in addition to dropping ACUR ended up closing the day at a new 52 week low.As well as the drop in value, Acura Pharmaceuticals, Inc. hit a new 52 week low of $0.10, breaking the previous low of $0.10 from earlier this April. Two technical ‘scores’ for companies to be aware of are the Altman Z1 and the Piotroski2 scores. ACUR scored rather low for both, which could be indicators of trouble down the road (the Altman Z-Score is -197.80, and the Piotroski Score is 2). In addition to the stock finishing lower, the trading volumes were only 43% of normal which could be an indication of investor uncertainty.
ACUR was outperformed by the rest of the Healthcare sector which went down only 0.31%.
Acura Pharmaceuticals, Inc. Info
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address medication abuse and misuse. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide. The company was founded in 1935 and is based in Palatine, Illinois.
All amounts in USD unless otherwise indicated
(1) The Altman Z-Score calculation was first published in 1968 by Edward I. Altman, and is used for predicting the probability that a firm will go into bankruptcy within two years. An Altman Z-Score below 1.8 (Remember that Acura Pharmaceuticals, Inc.’s score is -197.80) is the trigger to be alert for this situation. Some analysts believe this score is less relevant for some companies, in particular companies operating to accumulate users that may run at huge losses to scale up.
(2) The Piotrosky score is used to determine the best value stocks with nine being the best and zero being the worst. It is based on specific aspects of the company’s financial statements, such as positive net income, operating cash flow and asset turnover ratio. A score 0 0 is the worst (Acura Pharmaceuticals, Inc.’s score is ), and 9 is the best.
Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.